Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers

Priya Muralidharan, Evan Mallory, Monica Malapit, Hayes Don, Heidi M. Mansour

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Nanomedicine is making groundbreaking achievements in drug delivery. The versatility of nanoparticles has given rise to its use in respiratory delivery that includes inhalation aerosol delivery by the nasal route and the pulmonary route. Due to the unique features of the respiratory route, research in exploring the respiratory route for delivery of poorly absorbed and systemically unstable drugs has been increasing. The respiratory route has been successfully used for the delivery of macromolecules like proteins, peptides, and vaccines, and continues to be examined for use with small molecules, DNA, siRNA, and gene therapy. Phospholipid nanocarriers are an attractive drug delivery system for inhalation aerosol delivery in particular. Protecting these phospholipid nanocarriers from pulmonary immune system attack by surface modification by polyethylene glycol (PEG)ylation, enhancing mucopenetration by PEGylation, and sustaining drug release for controlled drug delivery are some of the advantages of PEGylated liposomal and proliposomal inhalation aerosol delivery. This review discusses the advantages of using PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery through the nasal and pulmonary routes as inhalation aerosols.

Original languageEnglish (US)
Pages (from-to)333-353
Number of pages21
JournalPharmaceutics
Volume6
Issue number2
DOIs
StatePublished - Jun 20 2014

Fingerprint

Dry Powder Inhalers
Inhalation
Phospholipids
Aerosols
Genetic Therapy
Lung
Pharmaceutical Preparations
Nanomedicine
Nasal Sprays
Subunit Vaccines
Therapeutics
Drug Delivery Systems
Nose
Nanoparticles
Small Interfering RNA
Immune System
Research
Proteins

Keywords

  • Aerosol
  • Lung
  • Nasal
  • PEGylated inhalation powders
  • PEGylated liposomes
  • PEGylated micelles
  • Solid-state PEGylated bilayer nanocarriers
  • Sterically stabilized nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers. / Muralidharan, Priya; Mallory, Evan; Malapit, Monica; Don, Hayes; Mansour, Heidi M.

In: Pharmaceutics, Vol. 6, No. 2, 20.06.2014, p. 333-353.

Research output: Contribution to journalArticle

@article{67f5f30d4d314f6f964e94767c372daa,
title = "Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers",
abstract = "Nanomedicine is making groundbreaking achievements in drug delivery. The versatility of nanoparticles has given rise to its use in respiratory delivery that includes inhalation aerosol delivery by the nasal route and the pulmonary route. Due to the unique features of the respiratory route, research in exploring the respiratory route for delivery of poorly absorbed and systemically unstable drugs has been increasing. The respiratory route has been successfully used for the delivery of macromolecules like proteins, peptides, and vaccines, and continues to be examined for use with small molecules, DNA, siRNA, and gene therapy. Phospholipid nanocarriers are an attractive drug delivery system for inhalation aerosol delivery in particular. Protecting these phospholipid nanocarriers from pulmonary immune system attack by surface modification by polyethylene glycol (PEG)ylation, enhancing mucopenetration by PEGylation, and sustaining drug release for controlled drug delivery are some of the advantages of PEGylated liposomal and proliposomal inhalation aerosol delivery. This review discusses the advantages of using PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery through the nasal and pulmonary routes as inhalation aerosols.",
keywords = "Aerosol, Lung, Nasal, PEGylated inhalation powders, PEGylated liposomes, PEGylated micelles, Solid-state PEGylated bilayer nanocarriers, Sterically stabilized nanoparticles",
author = "Priya Muralidharan and Evan Mallory and Monica Malapit and Hayes Don and Mansour, {Heidi M.}",
year = "2014",
month = "6",
day = "20",
doi = "10.3390/pharmaceutics6020333",
language = "English (US)",
volume = "6",
pages = "333--353",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers

AU - Muralidharan, Priya

AU - Mallory, Evan

AU - Malapit, Monica

AU - Don, Hayes

AU - Mansour, Heidi M.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Nanomedicine is making groundbreaking achievements in drug delivery. The versatility of nanoparticles has given rise to its use in respiratory delivery that includes inhalation aerosol delivery by the nasal route and the pulmonary route. Due to the unique features of the respiratory route, research in exploring the respiratory route for delivery of poorly absorbed and systemically unstable drugs has been increasing. The respiratory route has been successfully used for the delivery of macromolecules like proteins, peptides, and vaccines, and continues to be examined for use with small molecules, DNA, siRNA, and gene therapy. Phospholipid nanocarriers are an attractive drug delivery system for inhalation aerosol delivery in particular. Protecting these phospholipid nanocarriers from pulmonary immune system attack by surface modification by polyethylene glycol (PEG)ylation, enhancing mucopenetration by PEGylation, and sustaining drug release for controlled drug delivery are some of the advantages of PEGylated liposomal and proliposomal inhalation aerosol delivery. This review discusses the advantages of using PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery through the nasal and pulmonary routes as inhalation aerosols.

AB - Nanomedicine is making groundbreaking achievements in drug delivery. The versatility of nanoparticles has given rise to its use in respiratory delivery that includes inhalation aerosol delivery by the nasal route and the pulmonary route. Due to the unique features of the respiratory route, research in exploring the respiratory route for delivery of poorly absorbed and systemically unstable drugs has been increasing. The respiratory route has been successfully used for the delivery of macromolecules like proteins, peptides, and vaccines, and continues to be examined for use with small molecules, DNA, siRNA, and gene therapy. Phospholipid nanocarriers are an attractive drug delivery system for inhalation aerosol delivery in particular. Protecting these phospholipid nanocarriers from pulmonary immune system attack by surface modification by polyethylene glycol (PEG)ylation, enhancing mucopenetration by PEGylation, and sustaining drug release for controlled drug delivery are some of the advantages of PEGylated liposomal and proliposomal inhalation aerosol delivery. This review discusses the advantages of using PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery through the nasal and pulmonary routes as inhalation aerosols.

KW - Aerosol

KW - Lung

KW - Nasal

KW - PEGylated inhalation powders

KW - PEGylated liposomes

KW - PEGylated micelles

KW - Solid-state PEGylated bilayer nanocarriers

KW - Sterically stabilized nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84902961070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902961070&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics6020333

DO - 10.3390/pharmaceutics6020333

M3 - Article

AN - SCOPUS:84902961070

VL - 6

SP - 333

EP - 353

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 2

ER -